Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProStrakan Group and JapanBridge have announced an exclusive licence granted to JapanBridge to develop and commercialize Sancusom, a granisetron transdermal delivery system in Japan, China and several other nations throughout South East Asia.
Subscribe to our email newsletter
Under the terms of the agreement, JapanBridge has agreed to pay ProStrakan more than $26 million in upfront and milestone payments, subject to the achievement of certain approvals and sales targets. ProStrakan will exclusively supply Sancuso to JapanBridge in Japan, the People’s Republic of China, Taiwan, Singapore and Malaysia and will receive an undisclosed royalty rate on sales generated in these countries.
Sancuso is ProStrakan’s novel, patent-protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting.
Wilson Totten, CEO of ProStrakan, said: “In JapanBridge we have a dynamic partner with the capabilities and knowledge to commercialize Sancuso in Japan, an important and dynamic market for transdermal treatments, and elsewhere in East and South East Asia and help us to establish this product as a valuable treatment for chemotherapy patients at risk of nausea and vomiting.”